Bevacizumab in hereditary hemorrhagic telangiectasia.
Prithviraj
P
Bose
Jennifer L
JL
Holter
George B
GB
Selby
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004359:Drug Therapy, Combination; D005293:Ferritins / Q000097:blood; D006801:Humans; D007262:Infusions, Intravenous; D007501:Iron / Q000627:therapeutic use*; D008297:Male; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000097:blood / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D005293:Ferritins; D007501:Iron